Focal And Global Brain Measurements in Siblings of Patients With Schizophrenia

Heleen B. M. Boos*, Wiepke Cahn, Neeltje E. M. van Haren, Eske M. Derks, Rachel M. Brouwer, Hugo G. Schnack, Hilleke E. Hulshoff Pol, and René S. Kahn

Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, the Netherlands

*To whom correspondence should be addressed; Department of Psychiatry, A.00.241 University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands; tel: +31-88-7559931, fax: +31-88-7555466, e-mail h.b.m.boos@umcutrecht.nl

Background: It remains unclear whether structural brain abnormalities in schizophrenia are caused by genetic and/or disease-related factors. Structural brain abnormalities have been found in nonpsychotic first-degree relatives of patients with schizophrenia, but results are inconclusive. This large magnetic resonance imaging study examined brain structures in patients with schizophrenia, their nonpsychotic siblings, and healthy control subjects using global and focal brain measurements. Methods: From 155 patients with schizophrenia, their 186 nonpsychotic siblings, and 122 healthy controls (including 25 sibling pairs), whole-brain scans were obtained. Segmentations of total brain, gray matter (GM), and white matter of the cerebrum, lateral and third ventricle, and cerebellum volumes were obtained. For each subject, measures of cortical thickness and GM density maps were estimated. Group differences in volumes, cortical thickness, and GM density were analyzed using Structural Equation Modeling, hence controlling for familial dependency of the data. Results: Patients with schizophrenia, but not their nonpsychotic siblings, showed volumetric differences, cortical thinning, and reduced GM density as compared with control subjects. Conclusions: This study did not reveal structural brain abnormalities in nonpsychotic siblings of patients with schizophrenia compared with healthy control subjects using multiple imaging methods. Therefore, the structural brain abnormalities observed in patients with schizophrenia are for the largest part explained by disease-related factors.

Key words: structural magnetic resonance imaging/schizophrenia/siblings/family study/cortical thickness/voxel-based morphometry

Schizophrenia is characterized by gray matter (GM) reductions in cortical and subcortical regions, but the underlying mechanisms causing these abnormalities are largely unknown. Twin studies suggest that genetic influences play a role,1–3 but there is also convincing evidence that environmental influences, such as antipsychotic medication,4–7 obstetric complications,8–10 and cannabis use11–13 are involved. Furthermore, brain abnormalities appear to be related to clinical features such as duration of (untreated) psychosis14–16 and outcome.17,18

As the heritability to develop schizophrenia is estimated to be 81%,19 it is thought that the brain abnormalities reported in schizophrenia may also be present in unaffected relatives of patients with this illness. Indeed, a meta-analysis, including 23 studies, reported volumetric decreases in the hippocampus and GM, as well as increases in third ventricle volume in relatives of patients with schizophrenia compared with healthy control subjects.20 This meta-analysis pooled data from neuroimaging studies (largest study: n = 183) that examined various groups of relatives (ie, twins, parents, offspring, and siblings), all carrying their own specific genetic and environmental risk factors. The studies included in this meta-analysis did not provide enough data to examine the effects of age, which is relevant as offspring and young siblings are still at risk to develop the illness, while older siblings and parents are most likely beyond the age of risk. In addition, structural brain abnormalities seem progressive, even in unaffected relatives.21

Magnetic resonance imaging (MRI) studies that were included in the meta-analysis and focused on siblings of patients with schizophrenia reported GM reductions, most pronounced in the temporal areas8,22 (but not23) and hippocampus.24 Studies that were published after this meta-analysis came out reported GM reductions in the posterior cingulate cortex22 and the inferior frontal gyrus.25 In addition, larger orbitofrontal white matter (WM) was found,27 but when cortical thickness was examined, no differences were found in siblings of patients as compared with healthy control subjects.25 The largest sibling study to date, including 115 patients with
schizophrenia, 192 nonpsychotic siblings, and 196 healthy control subjects, failed to find differences in global brain volumes, cortical thickness, and GM density between siblings and healthy control subjects. Interestingly, a study including siblings of patients with childhood-onset schizophrenia found no differences in GM volume and cortical thickness in siblings of 20 years and older, while in the younger siblings decreased (parietal) GM volume, as well as cortical thinning were reported in the prefrontal and temporal cortices.

In summary, while smaller studies report reduced volumes in siblings of patients with schizophrenia compared with healthy control subjects, the largest study to date failed to find structural brain differences between these 2 groups. We therefore designed this large study of 155 patients with schizophrenia, 186 of their related (relatively young) nonpsychotic siblings, and 122 age-matched healthy control subjects (including 25 sibling pairs). Cortical and subcortical brain structures were examined by applying volumetric measurements, cortical thickness, and voxel-based morphometry (VBM). We hypothesized that nonpsychotic siblings show a similar but less pronounced pattern of structural brain differences relative to patients with schizophrenia as compared with healthy control subjects. As earlier studies reported that schizotypy was found to a much higher degree in first-degree relatives compared with control subjects, we hypothesized that these brain differences are related to (sub)clinical characteristics present in the siblings.

Materials and Methods

Participants

A total of 155 patients with schizophrenia, 186 related nonpsychotic siblings, and 122 healthy control subjects (including 25 sibling pairs) participated in this study. The recruitment was part of the baseline measurement of an ongoing longitudinal study in the Netherlands (Genetic Risk and Outcome of Psychosis; GROUP). From this study, subjects were recruited at the University Medical Center Utrecht, Utrecht, the Netherlands.

Eligible patients had to fulfill the following criteria: (1) age between 16 and 50 years, (2) meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for a nonaffective psychotic disorder (including schizophrenia, schizophreniform disorder, and schizoaffective disorder), (3) fluent in Dutch, and (4) able and willing to give written informed consent. Eligible siblings (brothers and/or sisters) of participating probands had to fulfill the criteria of (1) age between 16 and 50 years, (2) fluent in Dutch, and (3) able and willing to give written informed consent. Eligible healthy control subjects had to fulfill the criteria of (1) age between 16 and 50 years, (2) no lifetime psychotic disorder and/or use of lithium medication (in the past), (3) no first- or second-degree family member with a lifetime psychotic disorder, (4) fluent in Dutch, and (5) able and willing to give written informed consent.

Patients and controls identified as potentially eligible were asked to provide consent for assessment and for contacting their siblings. Control subjects were selected through a system of random mailings to addresses in the catchment areas. Presence or absence of psychopathology was established by using Comprehensive Assessment of Symptoms and History interview (CASH), performed by at least 1 independent rater who was trained to assess this interview. Diagnosis was based on the DSM-IV criteria. Of all subjects, urine was screened for cocaine, amphetamines, and for cannabis. Subjects with substance dependence/abuse (based on the criteria of the Composite International Diagnostic Interview [sections B, J, and L]) and a major medical or neurological illness were excluded.

Written informed consent was obtained from all subjects, and the study was approved by the Medical Ethics Committee for Research in Humans (METC) of the University Medical Center Utrecht.

Clinical And Neuropsychological Assessments

To evaluate severity of symptoms in patients with schizophrenia, the Positive and Negative Syndrome Scale (PANSS) was performed. In siblings and healthy control subjects, the Structured Interview for Schizotypy-Revised (SIS-R) was administered. The SIS-R is a semistructured interview containing 20 schizotypal symptoms and 11 schizotypal signs, rated on a 4-point scale. Scores were subdivided into positive, negative, and total schizotypal features. Furthermore, the Dutch translation of the Family Interview for Genetic Studies (FIGS) was used to estimate the presence of a psychiatric illness in first- and/or second-degree family members.

Imaging And Preprocessing

Structural MRI scans of the whole brain were obtained on a 1.5-T Achieva scanner (Philips, Best, the Netherlands). A 3-dimensional (3D), T1-weighted coronal spoiled-gradient echo scan of the whole head (256 × 256 matrix, echo time [TE] = 4.6 ms, repetition time [TR] = 30 ms, flip angle = 30°, 160–180 contiguous slices; 1 × 1 × 1.2 mm³ voxels, field of view [FOV] = 256 mm; 70%) was acquired. Furthermore, a single-shot echo planar imaging scan was made as part of a diffusion tensor imaging series (SENSE factor 2.5; flip angle = 90°; 60 transverse slices of 2.5 mm; no gap; 128 × 96 acquisition matrix; FOV = 120 mm; TE = 78 ms) together with a magnetization transfer imaging scan (60 transverse slices of 2.5 mm; no gap; 128 × 96 acquisition matrix; FOV = 240 mm; flip angle = 8°; TE = 4.5 ms; TR = 37.5 ms).
Volumetric Processing
The T1-weighted images were automatically put into Talairach orientation without scaling, by registering them to a model brain. The 2 other scans were registered to the T1-weighted image by minimizing a mutual information joint entropy function. The coregistered scans were used for automatic segmentation of the intracranial volume, based on histogram analysis and morphology operations. The intracranial segment served as a mask for all further segmentation steps. The T1-weighted images were used for automatic segmentation of the intracranial and WM of the cerebrum. In short, pure GM and WM were used for segmentation of total brain (TB), GM, and WM of the cerebrum. In this step, the partial volume GM and WM segments with voxels of 1 × 1 × 1.2 mm³ were blurred by a 3D Gaussian kernel (FWHM = 8 mm) to gain statistical power. The voxel values of these blurred partial volume GM and WM maps (between 0 and 1) reflect the local presence, or density, of GM or WM, respectively. These images are referred to as “density maps.” To compare brain tissue at the same anatomical location in all subjects, the GM and WM segments were transformed into a standardized coordinate system (the model space). These transformations were calculated in 2 steps. First, the T1-weighted images were linearly transformed to the model brain. In this linear step, a mutual information metric was optimized. In the second step, nonlinear (elastic) transformations were calculated to register the linearly transformed images to the model brain up to a scale of 4 mm (FWHM), thus removing global shape differences between brains but retaining local differences. For this step, the program ANIMAL was used. The GM and WM density maps were now transformed to the model space by applying the concatenated linear and nonlinear transformations. Finally, the maps were resampled to voxels of size 2 × 2 × 2.4 mm³. Voxel values of average GM density below 0.1 were excluded from the GM density voxel-based analysis. Using “nonmodulated” VBM analyses allow for direct investigation of regional differences in brain areas without being confounded by overall brain size, ie, these individual differences in brain size and shape have been removed by linear and nonlinear transformations.

Statistical Analysis
Demographic and Diagnostic Data. Data were examined for outliers and normality of the distribution, using the Kolmogorov-Smirnov test for significance. To assess whether the groups differed on demographic variables, univariate analyses of variance were conducted for noncategorical variables and χ² tests for categorical variables.
SPSS 15.0 statistical package for Windows (SPSS Inc., Chicago, Illinois) was employed for analyses of demographic data.

**Group Differences in Brain Volumes, Cortical Thickness, And GM Density Maps.** In the full model, TB, GM, WM, lateral ventricle, third ventricle, and cerebellum volumes were regressed on intracranial volume, gender, age, handedness, and group status (patients vs siblings vs healthy control subjects). Cortical thickness and GM density (VBM) were regressed on gender, age, handedness, and group status. Relatedness in the patient-sibling pairs and control pairs was accounted for in the covariance structure by allowing dependencies between the residuals in the regression analyses. Group effects were tested by comparing the $-2 \log$-likelihoods of 2 nested models: a model that does allow for group effects on structural brain measures (the full model) and a model that does not allow for such an effect. The difference in $-2 \log$-likelihood between these models is $\chi^2$ distributed. A $\chi^2 > 3.84$ ($1 \text{ df}$) indicates a significant difference at $\alpha = .05$ and depicts that the discarded effect (ie, group effect) cannot be left out of the model without seriously reducing the goodness of fit.

For group effects in volumes, cortical thickness, and VBM, mixed model analysis was implemented using Structural Equation Modeling (SEM) with Mx software for Windows (Department of Psychiatry, Virginia Commonwealth University Richmond, Virginia). The present study aimed to examine a large group of families and variables. A distinction was made between mutual correlations between siblings and correlations between healthy control subjects. SEM is a useful design for such studies. To evaluate the differences in cortical thickness, a vertex-by-vertex analysis was carried out. In each vertex, group differences in cortical thickness were calculated using regression analyses with group, age, gender, and handedness as covariates. This produced $\chi^2$ statistics at each vertex, one for the effect of group, one for the effect of age, one for the effect of gender, and one for the effect of handedness. Statistical maps were created showing significant differences in cortical thickness between groups. For those cortical areas that showed significant differences, the most significant vertex was identified visually using the cortical surface viewer brain-view developed at the Montreal Neurological Institute.

To evaluate differences in GM density, regression analysis was done through all brains for each voxel separately in the GM and WM density maps. Similar to the cortical thickness analysis, this produced $\chi^2$ statistics at each voxel.

In all statistical analyses, a correction for multiple comparisons was carried out according to the false discovery rate (FDR).

**Associations With Severity of Illness.** To address whether in patients, structural brain differences depend on severity of illness, post hoc analyses were performed. Brain measures were regressed on PANSS-positive symptoms scores, PANSS-negative symptoms scores, and PANSS total scores. For 8 patients, PANSS scores were missing. These were excluded from the analysis.

**Associations With Schizotypy.** For the combined sample of siblings and control subjects, post hoc analyses were performed to address whether there is an association between positive or negative schizotypal features as measured with the SIS-R and brain measures. For 3 siblings and 1 healthy control subject, SIS-R scores were missing. These were excluded from the analysis.

**Results**

**Demographic And Diagnostic Data**

For demographic analyses, see table 1. No differences between groups were found for age (siblings: 27.54 years [SD = 6.75]; patients with schizophrenia: mean age = 26.91 years [SD = 5.58]; and healthy control subjects: 27.53 years [SD = 8.24]), parental educational level (defined as the total number of years of education), and handedness. Groups differed significantly in gender distribution; male and female subjects being equally divided within the siblings (45.7% male) and control subjects (50.0%) but not in the patient group (80.6% male). Groups differed significantly in Wechsler Adult Intelligence Scale IQ (siblings: mean IQ = 100.9 [SD = 15.10]; patients with schizophrenia: mean IQ = 93.3 [SD = 15.70]; healthy control subjects: mean IQ = 110.9 [SD = 14.60]). The majority of patients (90%) were taking antipsychotic medication at the time of scan, with olanzapine and risperdone being most often prescribed ($N = 55$ and $N = 27$, respectively). In patients, mean duration of illness was 4.02 years (SD = 3.63).

**Global Brain Volumes**

After controlling for age, gender, intracranial volume, and handedness, nonpsychotic siblings did not differ from healthy control subjects in brain volumes. Patients with schizophrenia showed significant reductions in TB ($\chi^2 = 23.72, P < .01$), GM ($\chi^2 = 10.82, P < .01$), and WM volumes ($\chi^2 = 6.62, P = .01$) compared with healthy control subjects (see table 2). In addition, increased lateral ($\chi^2 = 14.65, P < .01$) and third ventricle ($\chi^2 = 6.94, P < .01$) volumes were found in patients relative to healthy control subjects. We have performed additional analyses in which we compared patients with their related siblings. The results of these analyses were similar to the results of the comparison of patients with control subjects. Post hoc analyses showed no association between brain volumes and dose or type of medication at inclusion nor did cannabis use (lifetime or past year) affect our results in patients with schizophrenia. In urine screening, 19 patients, 18 siblings, and 6 healthy control subjects...
were positive for cannabis, cocaine, or amphetamines at inclusion. Excluding these subjects from the analyses did not alter the results.

After controlling for IQ or parental education level (including age, gender, intracranial volume, and handedness), results were similar to those described above. Furthermore, because there were more male than female patients, a separate analysis was performed for only male subjects ($n = 113$ patients; $n = 84$ siblings; $n = 60$ healthy control subjects). The results of this analysis were similar to the results described above.

### Cortical Thickness

In focal cortical thickness analyses, nonpsychotic siblings did not show differences in cortical thickness compared with the healthy control subjects. Patients with schizophrenia showed cortical thinning compared with healthy control subjects. Figure 1 shows the statistical difference map of this analysis, corrected for the effect of age, sex, and handedness.

### Table 1. Demographic Information

<table>
<thead>
<tr>
<th></th>
<th>Patients ($N = 155$)</th>
<th>Siblings ($N = 186$)</th>
<th>Healthy Control Subjects ($N = 122$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (y)</strong></td>
<td>26.91 (5.6) [18.5–43.3]</td>
<td>27.5 (6.8) [16.6–50.5]</td>
<td>27.5 (8.2) [17.1–49.4]</td>
</tr>
<tr>
<td><strong>Sex (M/F)</strong></td>
<td>125/30 (80.6% male)</td>
<td>85/101 (45.7% male)</td>
<td>61/61 (50.0% male)</td>
</tr>
<tr>
<td><strong>Handedness (R/L)</strong></td>
<td>143/12 (92.3% right)</td>
<td>166/20 (89.2% right)</td>
<td>108/14 (88.5% right)</td>
</tr>
<tr>
<td><strong>Parental education level (completed in y)</strong></td>
<td>13.04 (3.6)</td>
<td>13.39 (3.1)</td>
<td>13.5 (3.1)</td>
</tr>
<tr>
<td><strong>Subject education level (completed in y)</strong></td>
<td>12.04 (2.3)</td>
<td>13.30 (2.4)</td>
<td>14.02 (1.9)</td>
</tr>
<tr>
<td><strong>WAIS IQ</strong></td>
<td>93.32 (15.7) [63–136]</td>
<td>100.9 (15.10) [68–155]</td>
<td>110.9 (14.6) [73–144]</td>
</tr>
<tr>
<td><strong>Paranoid type (%)</strong></td>
<td>100 (64.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Schizoaffective disorder (%)</strong></td>
<td>20 (12.9)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Undifferentiated type (%)</strong></td>
<td>17 (11.0)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Disorganized type (%)</strong></td>
<td>7 (4.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Catatonic type (%)</strong></td>
<td>1 (0.6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Schizophreniform disorder (%)</strong></td>
<td>9 (5.8)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Residual type (%)</strong></td>
<td>1 (0.6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Bipolar disorder (%)</strong></td>
<td>0</td>
<td>7 (3.8)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Major depression (%)</strong></td>
<td>0</td>
<td>36 (19.4)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Schizotypal personality disorder (%)</strong></td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Other disorders (%)</strong></td>
<td>0</td>
<td>6 (3.2)</td>
<td>0</td>
</tr>
<tr>
<td><strong>No psychiatric disorder (%)</strong></td>
<td>0</td>
<td>136 (73.1)</td>
<td>122 (100)</td>
</tr>
</tbody>
</table>

|                      | 15.34 (5.7) [7–35] | 15.41 (5.5) [6–31] | 62.22 (17.17) [30–133] |
| **PANSS-positive symptoms score** | 0.19 (0.4) [0–2] | 0.18 (0.24) [0–1.3] | 0.20 (0.3) [0–1] |
| **PANSS-negative symptoms score** | 0.20 (0.3) [0–1] | 0.18 (0.21) [0–0.9] | 0.18 (0.21) [0–0.9] |

<table>
<thead>
<tr>
<th></th>
<th><strong>$\chi^2$ (Patients vs Siblings)</strong></th>
<th><strong>$\chi^2$ (Siblings vs Controls)</strong></th>
<th><strong>$\chi^2$ (Patients vs Controls)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial volume</td>
<td>2.34</td>
<td>1.26</td>
<td>1.27</td>
</tr>
<tr>
<td>Whole brain</td>
<td>44.58*</td>
<td>0.50</td>
<td>23.72*</td>
</tr>
<tr>
<td>Cerebral gray matter</td>
<td>17.00*</td>
<td>0.00</td>
<td>10.82*</td>
</tr>
<tr>
<td>Cerebral white matter</td>
<td>20.87*</td>
<td>1.65</td>
<td>6.62*</td>
</tr>
<tr>
<td>Lateral ventricle</td>
<td>17.24*</td>
<td>0.05</td>
<td>14.65*</td>
</tr>
<tr>
<td>Third ventricle</td>
<td>33.07*</td>
<td>3.84</td>
<td>6.94*</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>2.23</td>
<td>0.84</td>
<td>3.09</td>
</tr>
</tbody>
</table>

**Note:** M/F, male/female; R/L, right/left; WAIS, Wechsler Adult Intelligence Scale; PANSS, Positive and Negative Syndrome Scale; SIS-R, Structured Interview for Schizotypy-Revised.

*Significantly differed from both other groups.

*For 8 cases, information was missing.

*For 4 cases, information was missing.

### Table 2. Brain Volumes ml: Uncorrected mean (SD)

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>Patients ($N = 155$)</th>
<th>Siblings ($N = 186$)</th>
<th>Controls ($N = 122$)</th>
<th>$\chi^2$ (Patients vs Siblings)</th>
<th>$\chi^2$ (Siblings vs Controls)</th>
<th>$\chi^2$ (Patients vs Controls)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial volume</td>
<td>1550.66 (145.54)</td>
<td>1504.87 (137.38)</td>
<td>1528.53 (141.09)</td>
<td>2.34</td>
<td>1.26</td>
<td>1.27</td>
</tr>
<tr>
<td>Whole brain</td>
<td>1303.20 (128.90)</td>
<td>1286.24 (123.94)</td>
<td>1304.69 (133.59)</td>
<td>44.58*</td>
<td>0.50</td>
<td>23.72*</td>
</tr>
<tr>
<td>Cerebral gray matter</td>
<td>622.79 (62.08)</td>
<td>613.52 (59.70)</td>
<td>622.59 (66.61)</td>
<td>17.00*</td>
<td>0.00</td>
<td>10.82*</td>
</tr>
<tr>
<td>Cerebral white matter</td>
<td>510.32 (63.21)</td>
<td>507.65 (60.76)</td>
<td>512.66 (62.83)</td>
<td>20.87*</td>
<td>1.65</td>
<td>6.62*</td>
</tr>
<tr>
<td>Lateral ventricle</td>
<td>16.89 (9.10)</td>
<td>13.69 (7.95)</td>
<td>13.16 (5.83)</td>
<td>17.24*</td>
<td>0.05</td>
<td>14.65*</td>
</tr>
<tr>
<td>Third ventricle</td>
<td>0.91 (0.35)</td>
<td>0.71 (0.30)</td>
<td>0.78 (0.33)</td>
<td>33.07*</td>
<td>3.84</td>
<td>6.94*</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>157.42 (15.56)</td>
<td>152.69 (15.88)</td>
<td>156.59 (15.86)</td>
<td>2.23</td>
<td>0.84</td>
<td>3.09</td>
</tr>
</tbody>
</table>

**Note:** In the analyses, means were corrected for intracranial volume, age, gender, and handedness.

*Significant differences ($P < .01$).
Brain Measurements in Siblings

gender, and handedness, at a corrected threshold of $\chi^2 > 7.50$ for left and $\chi^2 > 5.82$ for right hemisphere (FDR; $\alpha = .05$, $df = 1$). As shown in figure 1 and table 3, cortical thinning in patients was most apparent bilaterally in the frontal and temporal cortex, with patients also showing cortical thinning bilaterally in the occipital cortex, Wernicke’s area, left parahippocampal and posterior cingulate gyrus, and right parietal and precentral cortex. Cortical thinning was found also in patients as compared with nonpsychotic siblings (at a corrected threshold of $\chi^2 > 7.52$ for left and $\chi^2 > 5.64$ for right hemisphere), being most pronounced in the bilateral frontal and temporal cortex, but also in the Wernicke’s area, the left parahippocampal and occipital gyrus, and the right parietal cortex. Patients did not show increased cortical thickness compared with healthy control subjects or nonpsychotic siblings.

Voxel-Based Morphometry

For GM density maps, nonpsychotic siblings did not reveal differences compared with healthy control subjects. Patients with schizophrenia were significantly different from healthy control subjects as shown in figure 2. The critical $\chi^2$ value of significance, corrected for multiple comparisons (FDR, $\alpha = .05$) was 9.34. After correction for age, gender, and handedness, patients showed decreased GM density, most pronounced in the anterior cingulate gyrus and the insula as compared with healthy control subjects but also in the temporal, occipital, parietal, and frontal cortex; the thalamus; and the head of caudate. Similar to results in the comparison of patients vs controls, patients were different from siblings. The critical $\chi^2$ value of significance, corrected for multiple comparisons (FDR, $\alpha = .05$), was 9.13. After correction, patients showed decreased GM density as compared with siblings most pronounced in the frontal cortex and the insula but also in the anterior cingulate, temporal, and parietal cortex; the head of caudate; and the occipital cortex.

Associations With PANSS

PANSS total symptom score was associated with TB ($\chi^2 = 4.32$, $P < .05$) and GM volume ($\chi^2 = 7.30$, $P < .01$), with decreased volumes related to higher scores. PANSS total positive symptom score was negatively associated with GM volume ($\chi^2 = 8.22$, $P < .01$) and positively with lateral ventricle volume ($\chi^2 = 5.49$, $P < .05$).

Associations With Schizotypy

In siblings and healthy control subjects, SIS-R total, positive, or negative scores were not related with brain volumes nor with cortical thickness and GM density maps.

Discussion

This cross-sectional imaging study including 463 subjects examined brain structures in a relatively young sample of patients with schizophrenia ($n = 155$), their nonpsychotic siblings ($n = 186$), and healthy control subjects ($n = 122$, including 25 sibling pairs), using various imaging techniques. Global brain volumes of nonpsychotic siblings were not different from those of healthy control subjects, nor did siblings and healthy control subjects differ in cortical thickness or GM density measured using a VBM approach. The paucity of cortical and subcortical brain differences in the siblings of patients is consistent with the findings from another large study in nonpsychotic
The siblings in our study were about 10 years younger compared with the sample of Goldman et al., and in these analyses, we were able to take into account relatedness as we included patient-sibling pairs, as well as healthy control sibling pairs. Our findings contrast with those of smaller imaging studies in nonpsychotic siblings (largest study; total $n = 155$) and studies, but not all, reported a relationship between clinical outcome and reduced GM volume.

Our study did find robust structural brain differences in patients with schizophrenia as compared with healthy control subjects. Indeed, we replicate the global volumetric abnormalities in patients with schizophrenia in TB, GM, WM, lateral ventricle, and third ventricle. Furthermore, the decreases in cortical thickness and GM density, particularly in the frontal and temporal cortex, as well as in the anterior cingulate cortex, are consistent with earlier studies and with those studies using a VBM approach. These most replicated findings in the inferior frontal, middle temporal, and the cingulate regions have been found to be associated with speech.

Thus, our findings that brain abnormalities are expressed in patients with schizophrenia but not in non-psychotic siblings suggest that brain abnormalities in schizophrenia mainly reflect processes related to the manifestation and/or treatment of the illness.

That the illness itself causes brain changes in schizophrenia is corroborated by the findings in ultra–high risk subjects and the association between brain changes and illness-related factors in schizophrenia. Only in those subjects who later converted to psychosis cortical GM deficits were found at baseline, but deficits were not found in those subjects who did not become psychotic over time. Furthermore, a longitudinal study in adolescents at ultra-high risk for psychosis showed that the development of psychosis was associated with progressive abnormalities around time of onset (which was not attributed to antipsychotic medication). In addition, studies that examined symptomatology in relation to brain imaging findings reported that reduced GM volume was related to duration of untreated psychosis and duration of psychosis. In addition, various other studies, but not all, reported a relationship between clinical outcome and reduced GM volume.

### Significance Differences in Cortical Thickness: Areas Showing Cortical Thinning in (a) Patients Compared With Healthy Control Subjects And (b) Patients Compared With Their Nonpsychotic Siblings

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>Talairach Coords; $x$, $y$, $z$</th>
<th>BA</th>
<th>Mean Patients</th>
<th>Mean Siblings</th>
<th>Mean Controls</th>
<th>$\chi^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilateral middle temporal</td>
<td>49, –32, 0</td>
<td>3</td>
<td>3.20 (0.24)</td>
<td>3.27 (0.25)</td>
<td>3.27 (0.21)</td>
<td>19.86</td>
</tr>
<tr>
<td>Bilateral inferior occipital</td>
<td>47, –78, –2</td>
<td>19</td>
<td>2.77 (0.27)</td>
<td>2.81 (0.22)</td>
<td>2.87 (0.25)</td>
<td>19.85</td>
</tr>
<tr>
<td>Bilateral superior frontal</td>
<td>10, 53, 42</td>
<td>8</td>
<td>3.51 (0.29)</td>
<td>3.61 (0.29)</td>
<td>3.63 (0.29)</td>
<td>19.13</td>
</tr>
<tr>
<td>Bilateral Wernicke’s area</td>
<td>–44, –29, 10</td>
<td>41</td>
<td>3.03 (0.20)</td>
<td>3.13 (0.21)</td>
<td>3.11 (0.22)</td>
<td>13.12</td>
</tr>
<tr>
<td>Bilateral orbitofrontal</td>
<td>7, 48, –14</td>
<td>11</td>
<td>3.05 (0.22)</td>
<td>3.12 (0.21)</td>
<td>3.15 (0.23)</td>
<td>12.19</td>
</tr>
<tr>
<td>Left superior occipital</td>
<td>–6, –88, 23</td>
<td>18</td>
<td>2.59 (0.17)</td>
<td>2.62 (0.19)</td>
<td>2.71 (0.20)</td>
<td>18.38</td>
</tr>
<tr>
<td>Left parahippocampal</td>
<td>–37, –30, –11</td>
<td>36</td>
<td>2.84 (0.19)</td>
<td>2.97 (0.20)</td>
<td>3.01 (0.20)</td>
<td>16.08</td>
</tr>
<tr>
<td>Left posterior cingulate</td>
<td>–3, –18, 31</td>
<td>23</td>
<td>3.10 (0.21)</td>
<td>3.16 (0.21)</td>
<td>3.19 (0.21)</td>
<td>12.95</td>
</tr>
<tr>
<td>Right hippocampal</td>
<td>34, –20, –13</td>
<td>19</td>
<td>2.99 (0.19)</td>
<td>3.14 (0.22)</td>
<td>3.19 (0.21)</td>
<td>34.72</td>
</tr>
<tr>
<td>Right inferior occipital</td>
<td>27, –68, –7</td>
<td>19</td>
<td>2.85 (0.17)</td>
<td>2.95 (0.17)</td>
<td>2.97 (0.17)</td>
<td>33.40</td>
</tr>
<tr>
<td>Right middle frontal</td>
<td>39, 26, –8</td>
<td>47</td>
<td>3.25 (0.29)</td>
<td>3.33 (0.29)</td>
<td>3.37 (0.29)</td>
<td>18.35</td>
</tr>
<tr>
<td>Right posterior cingulate</td>
<td>4, –50, 18</td>
<td>30</td>
<td>3.23 (0.29)</td>
<td>3.29 (0.29)</td>
<td>3.31 (0.29)</td>
<td>18.06</td>
</tr>
<tr>
<td>Right parietal</td>
<td>7, –75, 44</td>
<td>7</td>
<td>2.63 (0.19)</td>
<td>2.67 (0.19)</td>
<td>2.71 (0.19)</td>
<td>12.01</td>
</tr>
<tr>
<td>Right superior frontal</td>
<td>4, 10, 49</td>
<td>6</td>
<td>3.51 (0.29)</td>
<td>3.57 (0.29)</td>
<td>3.58 (0.29)</td>
<td>12.14</td>
</tr>
</tbody>
</table>

All significant with critical $\chi^2 (\alpha = .05) = 7.52$ (left hemisphere) and $\chi^2 (\alpha = .05) = 5.64$ (right hemisphere).

b) | Bilateral frontal pole | 18, 25, –24 | 47 | 2.78 (0.19) | 2.93 (0.20) | 2.87 (0.19) | 26.05  |
| Bilateral middle temporal | 48, –34, 0 | 41 | 3.20 (0.28) | 3.28 (0.28) | 3.27 (0.28) | 25.02  |
| Bilateral Wernicke’s area | –43, –29, 10 | 12 | 3.03 (0.21) | 3.13 (0.21) | 3.11 (0.21) | 23.63  |
| Bilateral lateral superior frontal | 12, 53, 40 | 8 | 3.29 (0.29) | 3.60 (0.29) | 3.61 (0.29) | 22.47  |
| Left parahippocampal | –9, –36, 4 | 27 | 2.21 (0.25) | 2.31 (0.25) | 2.31 (0.25) | 14.55  |
| Left occipital | –47, –75, 3 | 19 | 2.78 (0.19) | 2.85 (0.22) | 2.83 (0.21) | 11.19  |
| Right occipital | 33, –80, –12 | 19 | 2.73 (0.21) | 2.88 (0.21) | 2.84 (0.21) | 30.73  |
| Right posterior cingulate | 7, –51, 22 | 23 | 3.21 (0.21) | 3.28 (0.21) | 3.28 (0.21) | 18.88  |
| Right inferior frontal | 44, 47, 2 | 10 | 3.02 (0.21) | 3.09 (0.21) | 3.08 (0.21) | 18.37  |

All significant with critical $\chi^2 (\alpha = .05) = 7.52$ (left hemisphere) and $\chi^2 (\alpha = .05) = 5.64$ (right hemisphere).

Note: The table shows the anatomical location (brain area), Talairach coordinates (Talairach coords) and Brodman coordinates (BA). Mean (standard deviation) for each group is given with the statistics ($\chi^2$).
Indeed, in the present study, we found that severity of illness (total and positive symptoms) was associated with reduced GM and increased lateral ventricle volume.

There is also evidence that brain abnormalities reported in schizophrenia are related to the effects of antipsychotic treatment. While post hoc analyses failed to show an association, in cross-sectional non-randomized studies such as ours, it is not possible to rule out medication effects on brain structure completely. A study in macaque monkeys treated long term with olanzapine or haloperidol reported that cortical volume was reduced by both these agents. In contrast, in a prospective study of Lieberman et al., obtaining MRI scans at multiple intervals, brain morphology was found to be differentially affected by olanzapine and haloperidol over time. In addition, other studies in patients with schizophrenia showed that decrements in GM volume over time, particularly in prefrontal regions, were associated with the (cumulative) intake of typical but not of atypical antipsychotic medication.

Other nonshared environmental factors, such as obstetric complications, can result in brain abnormalities in patients with schizophrenia. Unfortunately, in our study, there was not sufficient information of obstetric complications to investigate its effects on structural brain abnormalities.

To date, the neurobiological processes that underlie the brain abnormalities in patients with schizophrenia remain unclear but may reflect anomalies of synaptic plasticity and abnormal brain maturation. Early (prenatal and perinatal) neurodevelopmental trauma may render the brain vulnerable to aberrant late neurodevelopmental processes, which may further interact with other causative factors associated with the onset of psychosis (e.g., substance use, stress, and dysregulation of the hypothalamic-pituitary-adrenal axis function). Around transition to psychosis, these processes together may disrupt further brain development. Indeed, it has been suggested that the brain changes in the early state of schizophrenia are the result of the “toxic” effect of the psychotic state. Another theory was raised which guide neuroimmunology/virology studies of schizophrenia and derives from a general theoretical focus on central nervous system viral reactivation-induced immunological changes leading to psychosis.

That the structural brain differences are under genetic control cannot be dismissed by the negative findings of our study. MRI studies in twins do report volume decreases in whole brain, GM and WM, or hippocampus in unaffected twins who are discordant for schizophrenia, but not all. These studies included monozygotic twins, sharing 100% of the genes with their sibling, and dizygotic twins, sharing 50% of the genes. Unfortunately, in our study, there was not sufficient information of obstetric complications to investigate its effects on structural brain abnormalities.

Indeed, it has been suggested that the brain changes in the early state of schizophrenia are the result of the “toxic” effect of the psychotic state. Another theory was raised which guide neuroimmunology/virology studies of schizophrenia and derives from a general theoretical focus on central nervous system viral reactivation-induced immunological changes leading to psychosis.

That the structural brain differences are under genetic control cannot be dismissed by the negative findings of our study. MRI studies in twins do report volume decreases in whole brain, GM and WM, or hippocampus in unaffected twins who are discordant for schizophrenia, but not all. These studies included monozygotic twins, sharing 100% of the genes with their sibling, and dizygotic twins, sharing 50% of the genes. Interestingly, brain volume differences in twins discordant for schizophrenia were more pronounced in the monozygotic than in the dizygotic twins, compared with healthy control twins.

This suggests that the genetic contribution to brain volume reductions in schizophrenia may be subtle and is primarily detectable in subjects with high genetic loading, i.e., monozygotic discordant twins and not in the healthy siblings of patients with schizophrenia.

The presence of brain volume differences in unaffected twins but not siblings could also be explained by the contribution of environmental factors that are specific for twins, such as intrauterine viral infections, prenatal environment, and delivery complications. These are common environmental factors that patients share with their monozygotic co-twins, while they are not shared with...
a nontwin sibling. Stress may also be such a common environmental factor. The emotional burden of the disease can be considerable in siblings of patients with schizophrenia. For twins, who often have a close emotional relationship with each other, the experience of having a co-twin with a severe psychiatric disease like schizophrenia may represent a more pronounced burden.

Furthermore, the heterogeneity produced by the broadly recruited sample of unaffected siblings in our study may have undermined the apparently high statistical power. Some previous computational neuroanatomical studies assessed relatively homogenous groups of unaffected relatives of patients with schizophrenia, which were chosen deliberately to maximize power through “genetic enrichment,” including high-risk familial subject and relatives from multiply affected families.

Some limitations need to be addressed. First, a selection bias may have affected our results. This is reflected in that we included only siblings of patients who were willing to participate. Those siblings whom we were not able to include in the study may be of particular interest as they might share more (sub)clinical features with their ill proband. However, based on the FIGS, the included siblings were not different from those who were not included. Earlier studies reported that schizotypy was found to a much higher degree in first-degree relatives compared with healthy control subjects. As suggested by Diwadkar et al., relatives with high levels of schizotypy may define a hypervulnerable subsample among these relatives of patients with schizophrenia. Interestingly, in the present study, siblings and healthy control subjects were similar in schizotypal scores as measured with the SIS-R, suggesting that these siblings were possibly not vulnerable to develop schizophrenia. Second, there was a preponderance of men in the sample of patients compared with siblings and healthy control subjects. The epidemiological design of this study explains these differences. To minimize the effect of gender on brain structures, we controlled for this variable in all analyses. Male gender has been shown to be associated with larger cerebral volumes that disappear with head size correction. Greater decline of GM volume with age in males has also been reported in some but not other studies. Females have also been shown to have thicker cortex across many regions of the brain. As we know that gender but also age and handedness may influence brain structures, we have included these as covariates in our analyses. Third, it may be that cross-sectional MRI measurement might not be informative enough to find structural brain abnormalities in siblings of patients with schizophrenia. Fourth, it should be noted that the significant areas found in this study are indicative of locations of effects; their spatial extent is influenced by the smoothing of the data.

In conclusion, our study did not find structural brain abnormalities in nonpsychotic siblings of patients with schizophrenia compared with healthy control subjects, using multiple imaging methods. This suggests that the structural brain abnormalities found in patients are most likely related to the illness itself.

**Acknowledgments**

All authors report no competing interest.

**References**


66. DeLisi LE, Sakuma M, Maurizio AM, Relja M, Hoff AL. Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res. 2004;130:57–70.


